CXL Ophthalmics to Present Phase 2 Clinical Trial Results in Epi-On Cross-linking on November 14 at American Academy of Ophthalmology
11/09/2021
CXL Ophthalmics announced that the results of CXL-005, a phase 2 Trial in transepithelial (Epi-On) cross-linking, will be featured in the “Hot Topics 2021” session at AAO on November 14, at 11:30am (CST) at the Morial Convention Center in New Orleans.
Dr. Roy Rubinfeld, the company’s founder and Chief Scientific Officer, will deliver an invited presentation at the conclusion of the session (approximately 12:32pm). Conference attendees can view the presentation live in the La Nouvelle Orleans AB room and the session will be broadcast live for virtual attendees, as well as made available later on-demand.
See https://www.aao.org/annual-meeting for more information.